It is hard not to be a little excited about NSB right now... Preclinical work for MS and Pulmonary Fibrosis is now complete and the company will start working to get these into human trials, of which they will have 4 clinical programs with TAMs beginning with B for BILLIONS!
The company is set to conduct a PH1 Neurology (Safety Study) in humans to commence this quarter, my hope is that that safety study will also be used for MS and Pulmonary Fibrosis. That way the company will be go into 4 Ph2 trials next year! Very much looking forward to company updates as to how this graphic below will look with the now confirmed MS and PF clinical significance:
One thing is for certain, 4 Ph2 clinical trials will not have us capped at $50m!
Re: the Ph1 safety study, in the companies own words
GLTAH
It is hard not to be a little excited about NSB right now......
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
